Silence Therapeutics (SLN) Non-Current Deffered Revenue: 2019-2025
Historic Non-Current Deffered Revenue for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $55.3 million.
- Silence Therapeutics' Non-Current Deffered Revenue rose 173.37% to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year increase of 173.37%. This contributed to the annual value of $51.8 million for FY2024, which is 30.95% down from last year.
- According to the latest figures from Q3 2025, Silence Therapeutics' Non-Current Deffered Revenue is $55.3 million, which was down 1.88% from $56.3 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Non-Current Deffered Revenue ranged from a high of $97.7 million in Q4 2021 and a low of -$90.0 million during Q1 2022.
- For the 3-year period, Silence Therapeutics' Non-Current Deffered Revenue averaged around -$13.9 million, with its median value being -$71.3 million (2024).
- In the last 5 years, Silence Therapeutics' Non-Current Deffered Revenue crashed by 30.95% in 2024 and then skyrocketed by 176.67% in 2025.
- Quarterly analysis of 5 years shows Silence Therapeutics' Non-Current Deffered Revenue stood at $97.7 million in 2021, then dropped by 23.81% to $74.5 million in 2022, then increased by 0.72% to $75.0 million in 2023, then plummeted by 30.95% to $51.8 million in 2024, then skyrocketed by 173.37% to $55.3 million in 2025.
- Its last three reported values are $55.3 million in Q3 2025, $56.3 million for Q2 2025, and $53.3 million during Q1 2025.